Doubling Efficacy of Radiation Therapy for Cancer Tumors
Author: Georgia Health Sciences University
Published: 2011-12-17 : (Rev. 2012-09-21)
Synopsis and Key Points:
Scientists have devised a way to reduce lung cancer cells ability to repair the lethal double strand DNA breaks caused by radiation therapy.
Main DigestScientists may be able to double efficacy of radiation therapy - Scientists may have a way to double the efficacy and reduce the side effects of radiation therapy.
Radiation Therapy - Also known as radiation oncology, or radiotherapy, and sometimes abbreviated to XRT or DXT, is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells. Radiation therapy may be curative in a number of types of cancer if they are localized to one area of the body. It may also be used as part of curative therapy, to prevent tumor recurrence after surgery to remove a primary malignant tumor. Radiation therapy is synergistic with chemotherapy, and has been used before, during, and after chemotherapy in susceptible cancers.
Georgia Health Sciences University scientists have devised a way to reduce lung cancer cells' ability to repair the lethal double-strand DNA breaks caused by radiation therapy.
"Radiation is a great therapy - the problem is the side effects," said Dr. William S. Dynan, biochemist and Associate Director of Research and Chief, Nanomedicine and Gene Regulation at the GHSU Institute of Molecular Medicine and Genetics. "We think this is a way to get the same amount of cancer cell death with less radiation or use the same amount and maybe cure a patient that could not be cured before."
Radiation therapy capitalizes on radiation's ability to kill cells by causing double-strand breaks in DNA. But the fact that varying levels of radiation are essentially everywhere - food, air, the ground, etc. - means all cells, including cancer cells, have internal mechanisms to prevent the lethal breakage.
GHSU scientists are targeting the natural defense mechanisms by packaging a piece of an antibody against one of them with folate, which has easy access to most cells, particularly cancer cells. Many cancers, including the lung cancer cells they studied, have large numbers of folate receptors so that cancer cells get a disproportionate share of the package.
Previous efforts to destroy cancer cells' ability to avoid radiation damage have focused on receptors on their surface, said Dr. Shuyi Li, molecular biologist, pediatrician and corresponding author on the study in the International Journal of Radiation Oncology.
To get a more direct hit, the scientists took advantage of folate receptors as a point of entry by chemically binding folate with the small piece of their antibody, ScFv 18-2. The package heads straight for the cell nucleus where a different chemical environment breaks the bond, freeing ScFv 18-2 to attack the regulatory region of DNA-dependent protein kinase, an enzyme essential to DNA repair.
"We are joining a targeting molecule with a cargo," said Dynan. "This strategy targets one of the key enzymes so it's harder to repair," Li said. This makes cancer cells more vulnerable to radiation.
Dynan and Li say the approach could be used to deliver any number of drugs directly inside cancer cells. Future studies include looking at other cell entry points as well as other targets to ensure they have the most effective package. Studies to date have been in human lung cancer cells in culture, so next steps also need to include animal studies.
Their approach mimics a natural process called endocytosis in which cells engulf proteins and other substances they want to let inside but can't fit through normal doorways.
Folate receptors already are being used as direct entry points for chemotherapeutic drugs, including clinical studies of a new strategy for ovarian cancer. GHSU is participating in clinical trials of a therapy that pairs an agent too toxic to be delivered through the bloodstream with folate to better target one of the most deadly cancers.
Dynan is the Georgia Research Alliance Eminent Scholar in Molecular Biology. Dynan and Li are both faculty members in GHSU's Medical College of Georgia. Dynan also is a faculty member in the College of Graduate Studies.
- 1: Detectable Pre-cancerous State in Human Blood : Broad Institute of MIT and Harvard (2014/11/27)
- 2: Children's Hospital of Philadelphia Proton Therapy for Cancer Patients : Children's Hospital of Philadelphia (2010/05/27)
- 3: Turning Plant Virus Shells Against Human Cancers : Case Western Reserve University (2016/03/15)
- 4: Inhibiting Autophagy to Stop Cancer Tumors : University of Chicago Medical Center (2016/05/12)
- 5: New Approach to Control Cancer Not Eliminate It : Oregon State University (2016/08/26)
- 6: Chemotherapy: General Overview and Information : Disabled World (2009/03/23)
- 7: Discovery Paves Way for Pancreatic Cancer Treatment : University of Notre Dame (2016/11/12)
• Disabled World is strictly a news and information website provided for general informational purpose only and does not constitute medical advice. Materials presented are in no way meant to be a substitute for professional medical care by a qualified practitioner, nor should they be construed as such. Any 3rd party offering or advertising on disabled-world.com does not constitute endorsement by Disabled World. Please report outdated or inaccurate information to us.